- Home
- NXGL vs IMNN Comparison
NXGL vs IMNN Comparison
Compare NXGL & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXGL | IMNN |
|---|---|---|
| Founded | 1997 | 1982 |
| Country | United States | United States |
| Employees | 19 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8M | 11.0M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | NXGL | IMNN |
|---|---|---|
| Price | $0.66 | $3.16 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 244.9K | 62.3K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $50.77 | N/A |
| Revenue Next Year | $46.15 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.58 | $0.37 |
| 52 Week High | $3.02 | $9.32 |
Technical Indicators
Market Signals| Indicator | NXGL | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 38.88 | 53.28 |
| Support Level | $0.58 | $3.03 |
| Resistance Level | $1.76 | $3.61 |
| Average True Range (ATR) | 0.06 | 0.23 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 45.04 | 83.33 |
Price Performance
Historical ComparisonAbout NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).